AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Kidney Cancer Treatment Keeps Diversifying: Dual Immunotherapy, HIF-2α Inhibition, and the Search for a TKI-Free Interval
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Kidney Cancer Treatment Keeps Diversifying: Dual Immunotherapy, HIF-2α Inhibition, and the Search for a TKI-Free Interval
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Kidney Cancer Treatment Keeps Diversifying: Dual Immunotherapy, HIF-2α Inhibition, and the Search for a TKI-Free Interval
By Randy F. Sweis, MD
Frontline treatment of advanced renal cell carcinoma (RCC) now centers on a choice between dual immunotherapy and immunotherapy-TKI combinations, each with different tradeoffs in response rate versus durable remission.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Still Lags, But Treatment Options Are Expanding Fast
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Still Lags, But Treatment Options Are Expanding Fast
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Still Lags, But Treatment Options Are Expanding Fast
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
Enfortumab Vedotin Plus Pembrolizumab Has Reshaped Bladder Cancer, From Metastatic Disease to the Operating Room
By David VanderWeele, MD, PhD
For decades, platinum-based chemotherapy (cisplatin- or carboplatin-based regimens combined with gemcitabine) was the mainstay of treatment for metastatic urothelial cancer, with little improvement from added agents.
Enfortumab Vedotin Plus Pembrolizumab Has Reshaped Bladder Cancer, From Metastatic Disease to the Operating Room
By David VanderWeele, MD, PhD
For decades, platinum-based chemotherapy (cisplatin- or carboplatin-based regimens combined with gemcitabine) was the mainstay of treatment for metastatic urothelial cancer, with little improvement from added agents.
Enfortumab Vedotin Plus Pembrolizumab Has Reshaped Bladder Cancer, From Metastatic Disease to the Operating Room
By David VanderWeele, MD, PhD
For decades, platinum-based chemotherapy (cisplatin- or carboplatin-based regimens combined with gemcitabine) was the mainstay of treatment for metastatic urothelial cancer, with little improvement from added agents.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Colorectal Cancer: Exercise Pays for Itself, Aspirin's Role Stays Murky, and Some Patients Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays for Itself, Aspirin's Role Stays Murky, and Some Patients Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays for Itself, Aspirin's Role Stays Murky, and Some Patients Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.